Stroke, Vol 25, 2331-2336, Copyright © 1994 by American Heart Association
CM Helgason, KM Bolin, JA Hoff, SR Winkler, A Mangat, KL Tortorice and LD Brace
BACKGROUND AND PURPOSE: The ex vivo effect of aspirin (ASA) on platelet
aggregation, the platelet component of thrombosis, was studied at repeated
intervals in a cohort of patients taking aspirin for recurrent ischemic
stroke prevention to define the maintenance of efficacy over time. METHODS:
We administered increasing doses of aspirin (from 325 to 1300 mg/d) to
patients with previous ischemic stroke and determined the extent of
inhibition of platelet aggregation after 2 weeks and thereafter at
approximately 6-month intervals. RESULTS: Over 33 months, 306 patients had
platelet aggregation studies performed to define their initial response to
ASA therapy. Of these, 228 had complete and 78 had partial inhibition of
platelet aggregation at initial testing. To date, 119 of those who had
complete inhibition and 52 who had partial inhibition have undergone repeat
testing at least once. At repeat testing 39 of the 119 (32.7%) with
complete inhibition at initial testing had lost part of the antiplatelet
effect of ASA and converted from complete to partial inhibition without
change in ASA dosage. Of the 52 with partial inhibition at initial testing,
35 achieved complete inhibition either by ASA dosage escalation (in 325
mg/d increments) or fluctuation of response at the same dosage, but 8 of
those 35 (22.8%) had reverted to partial inhibition when tested again.
Overall, 8.2% of patients ultimately exhibited ASA resistance to 1300
mg/d-8 of 52 (15.4%) with partial inhibition and 6 of 119 (5.0%) with
complete inhibition at initial testing. CONCLUSIONS: The antiplatelet (and
presumably the antithrombotic) effect of a fixed dose of ASA is not
constant over time in all individuals. The mechanisms by which increased
dosage requirement or ASA resistance develops and the clinical significance
of this development are currently undefined.
ARTICLES
Development of aspirin resistance in persons with previous ischemic stroke
University of Illinois at Chicago, Department of Neurology, IL.
This article has been cited by other articles:
 |
|
 |
|
  F. Santilli, B. Rocca, R. De Cristofaro, S. Lattanzio, L. Pietrangelo, A. Habib, C. Pettinella, A. Recchiuti, E. Ferrante, G. Ciabattoni, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays implications for aspirin "resistance". J. Am. Coll. Cardiol., February 24, 2009; 53(8): 667 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Saw, E. H. Madsen, S. Chan, and E. Maurer-Spurej The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) Study J. Am. Coll. Cardiol., December 2, 2008; 52(23): 1826 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. BAKHRU and D. L. BHATT INTERPRETING THE CHARISMA STUDY: What is the role of dual antiplatelet therapy with clopidogrel and aspirin? Cleveland Clinic Journal of Medicine, April 1, 2008; 75(4): 289 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono and B. Rocca Aspirin: Promise and Resistance in the New Millennium Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): s25 - s32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Krasopoulos, S. J Brister, W S. Beattie, and M. R Buchanan Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis BMJ, January 26, 2008; 336(7637): 195 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson Platelet Function Monitoring in Patients With Coronary Artery Disease J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1822 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Gurbel, K. P. Bliden, J. DiChiara, J. Newcomer, W. Weng, N. K. Neerchal, T. Gesheff, S. K. Chaganti, A. Etherington, and U. S. Tantry Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Study Circulation, June 26, 2007; 115(25): 3156 - 3164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Meadows and D. L. Bhatt Clinical Aspects of Platelet Inhibitors and Thrombus Formation Circ. Res., May 11, 2007; 100(9): 1261 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Campbell, S. Smyth, G. Montalescot, and S. R. Steinhubl Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review JAMA, May 9, 2007; 297(18): 2018 - 2024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P Dorsch, J. S. Lee, D. R Lynch, S. P Dunn, J. E Rodgers, T. Schwartz, E. Colby, D. Montague, and S. S Smyth Aspirin Resistance in Patients with Stable Coronary Artery Disease with and without a History of Myocardial Infarction Ann. Pharmacother., May 1, 2007; 41(5): 737 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Undas, K. E. Brummel-Ziedins, and K. G. Mann Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions Blood, March 15, 2007; 109(6): 2285 - 2292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chaturvedi and J. S. Yadav The Role of Antiplatelet Therapy in Carotid Stenting for Ischemic Stroke Prevention Stroke, June 1, 2006; 37(6): 1572 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H Cavallari, C. M Helgason, L. D Brace, M. A. Viana, and E. A Nutescu Sex Difference in the Antiplatelet Effect of Aspirin in Patients with Stroke Ann. Pharmacother., May 1, 2006; 40(5): 812 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Michos, R. Ardehali, R. S. Blumenthal, R. A. Lange, and H. Ardehali Aspirin and Clopidogrel Resistance Mayo Clin. Proc., April 1, 2006; 81(4): 518 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Soman, M. F. Rafay, S. Hune, A. Allen, D. MacGregor, and G. deVeber The Risks and Safety of Clopidogrel in Pediatric Arterial Ischemic Stroke Stroke, April 1, 2006; 37(4): 1120 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Vorchheimer and R. Becker Platelets in Atherothrombosis Mayo Clin. Proc., January 1, 2006; 81(1): 59 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Mason, A. K. Jacobs, and J. E. Freedman Aspirin Resistance and Atherothrombotic Disease J. Am. Coll. Cardiol., September 20, 2005; 46(6): 986 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Saseen ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1398 - 1405. [Full Text] [PDF]
|
|
|
|
 |
|
 H Mani, B Luxembourg, C Klaffling, M Erbe, and E Lindhoff-Last Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements J. Clin. Pathol., July 1, 2005; 58(7): 747 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Papp, V. Havasi, J. Bene, K. Komlosi, L. Czopf, E. Magyar, C. Feher, G. Feher, B. Horvath, Z. Marton, et al. Glycoprotein IIIA Gene (PlA) Polymorphism and Aspirin Resistance: Is There Any Correlation? Ann. Pharmacother., June 1, 2005; 39(6): 1013 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Chimowitz, M. J. Lynn, H. Howlett-Smith, B. J. Stern, V. S. Hertzberg, M. R. Frankel, S. R. Levine, S. Chaturvedi, S. E. Kasner, C. G. Benesch, et al. Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis N. Engl. J. Med., March 31, 2005; 352(13): 1305 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sanderson, J. Emery, T. Baglin, and A.-L. Kinmonth Narrative Review: Aspirin Resistance and Its Clinical Implications Ann Intern Med, March 1, 2005; 142(5): 370 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Dyszkiewicz-Korpanty, E. P. Frenkel, and R. Sarode Approach to the Assessment of Platelet Function: Comparison between Optical-based Platelet-rich Plasma and Impedance-based Whole Blood Platelet Aggregation Methods Clinical and Applied Thrombosis/Hemostasis, January 1, 2005; 11(1): 25 - 35. [Abstract] [PDF]
|
|
|
|
|
|
M. Cattaneo Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 1980 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Houel, E. Mazoyer, B. Boval, M. Kirsch, E. Vermes, L. Drouet, and D. Y. Loisance Platelet activation and aggregation profile in prolonged external ventricular support J. Thorac. Cardiovasc. Surg., August 1, 2004; 128(2): 197 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Pulcinelli, P. Pignatelli, A. Celestini, S. Riondino, P. P. Gazzaniga, and F. Violi Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients J. Am. Coll. Cardiol., March 17, 2004; 43(6): 979 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-H. Chen, P.-Y. Lee, W. Ng, H.-F. Tse, and C.-P. Lau Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment J. Am. Coll. Cardiol., March 17, 2004; 43(6): 1122 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J Hankey and J. W Eikelboom Aspirin resistance BMJ, February 28, 2004; 328(7438): 477 - 479. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Alberts, D. L. Bergman, E. Molner, B. D. Jovanovic, I. Ushiwata, and J. Teruya Antiplatelet Effect of Aspirin in Patients With Cerebrovascular Disease Stroke, January 1, 2004; 35(1): 175 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Gum, K. Kottke-Marchant, P. A. Welsh, J. White, and E. J. Topol A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J. Am. Coll. Cardiol., March 19, 2003; 41(6): 961 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Eikelboom and G. J. Hankey Aspirin resistance:a new independent predictor of vascular events? J. Am. Coll. Cardiol., March 19, 2003; 41(6): 966 - 968. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sabatine and E. M. Antman The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 89S - 95S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Friend, I. Vucenik, and M. Miller Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia BMJ, January 11, 2003; 326(7380): 82 - 83. [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt, D. P. Chew, A. T. Hirsch, P. A. Ringleb, W. Hacke, and E. J. Topol Superiority of Clopidogrel Versus Aspirin in Patients With Prior Cardiac Surgery Circulation, January 23, 2001; 103(3): 363 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects Chest, January 1, 2001; 119(1_suppl): 39S - 63S. [Full Text] [PDF]
|
|
|
|
|
|
E. H. Awtry and J. Loscalzo Aspirin Circulation, March 14, 2000; 101(10): 1206 - 1218. [Full Text] [PDF]
|
|
|
|
 |
|
 O M P JOLOBE Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone J. Neurol. Neurosurg. Psychiatry, December 1, 1999; 67(6): 832 - 832. [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Treiman The Natural History of Asymptomatic Carotid Stenosis: Assessing the Risk and Rate of Disease Progression Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1999; 11(2): 95 - 109. [Abstract] [PDF]
|
|
|
|
|
|
R. G. Hart and M. J.G. Harrison Aspirin Wars : The Optimal Dose of Aspirin to Prevent Stroke Stroke, April 1, 1996; 27(4): 585 - 587. [Full Text]
|
|
|
|
|
|
H.J.M. Barnett, M. Kaste, H. Meldrum, and M. Eliasziw Aspirin Dose in Stroke Prevention : Beautiful Hypotheses Slain by Ugly Facts Stroke, April 1, 1996; 27(4): 588 - 592. [Full Text]
|
|
|
|
|
|
C. Patrono and G. J. Roth Aspirin in Ischemic Cerebrovascular Disease : How Strong Is the Case for a Different Dosing Regimen? Stroke, April 1, 1996; 27(4): 756 - 760. [Abstract] [Full Text]
|
|
|
|
|
|
J. W. Eikelboom, J. Hirsh, J. I. Weitz, M. Johnston, Q. Yi, and S. Yusuf Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events Circulation, April 9, 2002; 105(14): 1650 - 1655. [Abstract] [Full Text] [PDF]
|
|